Please assess the completion status of the following clinical trial:

Trial Title: Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Female patients ≥ 18 years of age. Confirmed breast cancer with bone metastasis. Pretreated with Zometa®, or Aredia (pamidronate) or all sequential regimens of both, for a minimum of 9 doses;~Exclusion Criteria:~Abnormal kidney function determined by serum creatinine levels. Current active dental problems including: ongoing infection of the teeth or jawbone; current exposed bone in the mouth; and current or prior diagnosis of osteonecrosis of the jaw.~Recent (within 8 weeks) or planned dental or jaw surgery (e.g., extraction, implants).~Diagnosis of metabolic bone disease other than osteoporosis (e.g., Paget's disease of bone).~Known hypersensitivity to Zometa. Treatment with other investigational drugs within 30 days prior to randomization.~Other protocol-defined exclusion criteria may have applied.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic acid every (q) 4 weeks (Type: EXPERIMENTAL): Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.
- Zoledronic acid q 12 weeks (Type: EXPERIMENTAL): Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.
- Placebo / zoledronic acid (Type: EXPERIMENTAL): Participants randomized to this arm received placebo but the arm was later dropped and participants in this arm were swithced to the zoledronic acid q 4 weeks according to a study amendment.

Based on this trial design, predict the completion outcome and termination type (if applicable).